JCA-Mauvernay Award
Launched in 2005 by the Japanese Cancer Association and Debiopharm Group
The JCA-Mauvernay Award is organized each year in collaboration with the Japanese Cancer Association (JCA). This award has a total value of CHF 25’000 and it aims at recognizing outstanding achievements in the field of oncology amongst Japanese researchers, in both the fundamental and the clinical aspects.
In 2014, the JCA-Mauvernay Award celebrated its 10th anniversary (watch the video here).
Press Releases
-
September 26, 2023
Debiopharm Recognizes Pioneering Japanese Cancer Research During The 82nd JCA-Mauvernay Award Ceremony
-
October 3, 2022
Debiopharm reinforces the bond between Swiss and Japanese cancer research with the 2022 JCA-Mauvernay Award Ceremony
-
October 4, 2021
Debiopharm Encourages Breakthough Cancer Research In Japan Through its Competitive JCA Mauvernay Award